Literaturverzeichnis

Abrams,E.S., Murdaugh,S.E., and Lerman,L.S. (1993). Comprehensive screening of the human KRAS2 gene for sequence variants. Genes Chromosomes Cancer *6*, 73-85.

Adams,J.M. and Cory,S. (2002). Apoptosomes: engines for caspase activation. Curr. Opin. Cell Biol. *14*, 715-720.

Almoguera,C., Shibata,D., Forrester,K., Martin,J., Arnheim,N., and Perucho,M. (1988). Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell *53*, 549-554.

Alves,F., Borchers,U., Padge,B., Augustin,H., Nebendahl,K., Kloppel,G., and Tietze,L.F. (2001a). Inhibitory effect of a matrix metalloproteinase inhibitor on growth and spread of human pancreatic ductal adenocarcinoma evaluated in an orthotopic severe combined immunodeficient (SCID) mouse model. Cancer Lett. *165*, 161-170.

Alves,F., Contag,S., Missbach,M., Kaspareit,J., Nebendahl,K., Borchers,U., Heidrich,B., Streich,R., and Hiddemann,W. (2001b). An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas *23*, 227-235.

Apolloni,A., Prior,I.A., Lindsay,M., Parton,R.G., and Hancock,J.F. (2000). H-ras but not K-ras traffics to the plasma membrane through the exocytic pathway. Mol. Cell Biol. *20*, 2475-2487.

Baltimore,D. (1970). RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature *226*, 1209-1211.

Banerji,S., Ni,J., Wang,S.X., Clasper,S., Su,J., Tammi,R., Jones,M., and Jackson,D.G. (1999). LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. J. Cell Biol. *144*, 789-801.

Bar-Sagi,D. (2001). A Ras by any other name. Mol. Cell Biol. *21*, 1441-1443.

Barbacid,M. (1987). ras genes. Annu. Rev. Biochem. *56*, 779-827.

Bardeesy,N. and DePinho,R.A. (2002). Pancreatic cancer biology and genetics. Nat. Rev. Cancer *2*, 897-909.

Bardeesy,N., Sharpless,N.E., DePinho,R.A., and Merlino,G. (2001). The genetics of pancreatic adenocarcinoma: a roadmap for a mouse model. Semin. Cancer Biol. *11*, 201-218.

Baumhueter,S., Dybdal,N., Kyle,C., and Lasky,L.A. (1994). Global vascular expression of murine CD34, a sialomucin-like endothelial ligand for L-selectin. Blood *84*, 2554-2565.

Bergers,G. and Benjamin,L.E. (2003). Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer *3*, 401-410.

Bissonnette,N. and Hunting,D.J. (1998). p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. Oncogene *16*, 3461-3469.

Blagosklonny,M.V. and el Deiry,W.S. (1996). In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. Int. J. Cancer *67*, 386-392.

Blandino,G., Levine,A.J., and Oren,M. (1999). Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene *18*, 477-485.

Bloomston,M., Zervos,E.E., and Rosemurgy,A.S. (2002). Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann. Surg. Oncol. *9*, 668-674.

Bordel,R., Laschke,M.W., Menger,M.D., and Vollmar,B. (2005). Inhibition of p53 during physiological angiogenesis in the hamster ovary does not affect extent of new vessel formation but delays vessel maturation. Cell Tissue Res. *320*, 427-435.

Bornstein,P., Agah,A., and Kyriakides,T.R. (2004). The role of thrombospondins 1 and 2 in the regulation of cell-matrix interactions, collagen fibril formation, and the response to injury. Int. J. Biochem. Cell Biol. *36*, 1115-1125.

Bos,J.L. (1989). ras oncogenes in human cancer: a review. Cancer Res. *49*, 4682-4689.

Bourne,H.R., Sanders,D.A., and McCormick,F. (1990). The GTPase superfamily: a conserved switch for diverse cell functions. Nature *348*, 125-132.

Brummelkamp,T.R., Bernards,R., and Agami,R. (2002). Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell *2*, 243-247.

Bruns,C.J., Harbison,M.T., Kuniyasu,H., Eue,I., and Fidler,I.J. (1999). In vivo selection and characterization of metastatic variants from human pancreatic adenocarcinoma by using orthotopic implantation in nude mice. Neoplasia. *1*, 50-62.

Buckbinder,L., Talbott,R., Seizinger,B.R., and Kley,N. (1994). Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. Proc. Natl. Acad. Sci. U. S. A *91*, 10640-10644.

Bujard,H. (1999). Controlling genes with tetracyclines. J. Gene Med. *1*, 372-374.

Bykov,V.J., Issaeva,N., Selivanova,G., and Wiman,K.G. (2002a). Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Carcinogenesis *23*, 2011-2018.

Bykov,V.J., Issaeva,N., Shilov,A., Hultcrantz,M., Pugacheva,E., Chumakov,P., Bergman,J., Wiman,K.G., and Selivanova,G. (2002b). Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat. Med. *8*, 282-288.

Cadwell,C. and Zambetti,G.P. (2001). The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene *277*, 15-30.

Carmeliet,P. and Jain,R.K. (2000). Angiogenesis in cancer and other diseases. Nature *407*, 249-257.

Cascallo,M., Mercade,E., Capella,G., Lluis,F., Fillat,C., Gomez-Foix,A.M., and Mazo,A. (1999). Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Ther. *6*, 428-436.

Cerny,W.L., Mangold,K.A., and Scarpelli,D.G. (1992). K-ras mutation is an early event in pancreatic duct carcinogenesis in the Syrian golden hamster. Cancer Res. *52*, 4507-4513.

Chen,X., Ko,L.J., Jayaraman,L., and Prives,C. (1996). p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes Dev. *10*, 2438-2451.

Chi,T.Y., Chen,G.G., Ho,L.K., and Lai,P.B. (2005). Establishment of a doxycycline-regulated cell line with inducible, doubly-stable expression of the wild-type p53 gene from p53-deleted hepatocellular carcinoma cells. Cancer Cell Int. *5*, 27.

Choy,E., Chiu,V.K., Silletti,J., Feoktistov,M., Morimoto,T., Michaelson,D., Ivanov,I.E., and Philips,M.R. (1999). Endomembrane trafficking of ras: the CAAX motif targets proteins to the ER and Golgi. Cell *98*, 69-80.

Coqueret,O. (2003). New roles for p21 and p27 cell-cycle inhibitors: a function for each cell compartment? Trends Cell Biol. *13*, 65-70.

Crespo,P. and Leon,J. (2000). Ras proteins in the control of the cell cycle and cell differentiation. Cell Mol. Life Sci. *57*, 1613-1636.

Dameron,K.M., Volpert,O.V., Tainsky,M.A., and Bouck,N. (1994). The p53 tumor suppressor gene inhibits angiogenesis by stimulating the production of thrombospondin. Cold Spring Harb. Symp. Quant. Biol. *59*, 483-489.

Delisser,H.M., Newman,P.J., and Albelda,S.M. (1993). Platelet endothelial cell adhesion molecule (CD31). Curr. Top. Microbiol. Immunol. *184*, 37-45.

Dergham,S.T., Dugan,M.C., Sarkar,F.H., and Vaitkevicius,V.K. (1998). Molecular alterations associated with improved survival in pancreatic cancer patients treated with radiation or chemotherapy. J. Hepatobiliary. Pancreat. Surg. *5*, 269-272.

Detjen,K.M., Farwig,K., Welzel,M., Wiedenmann,B., and Rosewicz,S. (2001). Interferon gamma inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis. Gut *49*, 251-262.

Digiuseppe,J.A., Hruban,R.H., Goodman,S.N., Polak,M., van den Berg,F.M., Allison,D.C., Cameron,J.L., and Offerhaus,G.J. (1994). Overexpression of p53 protein in adenocarcinoma of the pancreas. Am. J. Clin. Pathol. *101*, 684-688.

Dittmer,D., Pati,S., Zambetti,G., Chu,S., Teresky,A.K., Moore,M., Finlay,C., and Levine,A.J. (1993). Gain of function mutations in p53. Nat. Genet. *4*, 42-46.

DKFZ. www.dkfz.de. 2003.
Ref Type: Report

Do,T.N., Rosal,R.V., Drew,L., Raffo,A.J., Michl,J., Pincus,M.R., Friedman,F.K., Petrylak,D.P., Cassai,N., Szmulewicz,J., Sidhu,G., Fine,R.L., and Brandt-Rauf,P.W. (2003). Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene *22*, 1431-1444.

Donehower,L.A., Harvey,M., Slagle,B.L., McArthur,M.J., Montgomery,C.A., Jr., Butel,J.S., and Bradley,A. (1992). Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature *356*, 215-221.

Downward,J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer *3*, 11-22.

Ehrhardt,A., Ehrhardt,G.R., Guo,X., and Schrader,J.W. (2002). Ras and relatives--job sharing and networking keep an old family together. Exp. Hematol. *30*, 1089-1106.

Einhauer,A. and Jungbauer,A. (2001). Affinity of the monoclonal antibody M1 directed against the FLAG peptide. J. Chromatogr. A *921*, 25-30.

Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K., and Tuschl,T. (2001). Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature *411*, 494-498.

Endoline. www.endoline.de. 2007.
Ref Type: Internet Communication

Ferrara,N. (2001). Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol Cell Physiol *280*, C1358-C1366.

Fidler,I.J. (1991). Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev. *10*, 229-243.

Fidler,I.J. (1995). Modulation of the organ microenvironment for treatment of cancer metastasis. J. Natl. Cancer Inst. *87*, 1588-1592.

Fidler,I.J., Li,L.M., Ananthaswamy,H.N., Esumi,N., Radinsky,R., and Price,J.E. (1991). Correlation of growth capacity of cells in hard agarose with successful transfection by the activated c-Ha-ras oncogene and in vivo proliferative capacity at metastatic sites. Anticancer Res. *11*, 17-24.

Flamme,I., von Reutern,M., Drexler,H.C., Syed-Ali,S., and Risau,W. (1995). Overexpression of vascular endothelial growth factor in the avian embryo induces hypervascularization and increased vascular permeability without alterations of embryonic pattern formation. Dev. Biol. *171*, 399-414.

Forsythe,J.A., Jiang,B.H., Iyer,N.V., Agani,F., Leung,S.W., Koos,R.D., and Semenza,G.L. (1996). Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell Biol. *16*, 4604-4613.

Foster,B.A., Coffey,H.A., Morin,M.J., and Rastinejad,F. (1999). Pharmacological rescue of mutant p53 conformation and function. Science *286*, 2507-2510.

Fridman,J.S. and Lowe,S.W. (2003). Control of apoptosis by p53. Oncogene *22*, 9030-9040.

Friedman,P.N., Chen,X., Bargonetti,J., and Prives,C. (1993). The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc. Natl. Acad. Sci. U. S. A *90*, 3319-3323.

Friess,H., Berberat,P., Schilling,M., Kunz,J., Korc,M., and Buchler,M.W. (1996). Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J. Mol. Med. *74*, 35-42.

Ghaneh,P., Greenhalf,W., Humphreys,M., Wilson,D., Zumstein,L., Lemoine,N.R., and Neoptolemos,J.P. (2001). Adenovirus-mediated transfer of p53 and p16(INK4a) results in pancreatic cancer regression in vitro and in vivo. Gene Ther. *8*, 199-208.

Giaccia,A.J. and Kastan,M.B. (1998). The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. *12*, 2973-2983.

Ginsberg,D., Mechta,F., Yaniv,M., and Oren,M. (1991). Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci. U. S. A *88*, 9979-9983.

Giovanella,B.C., Yim,S.O., Stehlin,J.S., and Williams,L.J., Jr. (1972). Development of invasive tumors in the "nude" mouse after injection of cultured human melanoma cells. J. Natl. Cancer Inst. *48*, 1531-1533.

Gorunova,L., Hoglund,M., Andren-Sandberg,A., Dawiskiba,S., Jin,Y., Mitelman,F., and Johansson,B. (1998). Cytogenetic analysis of pancreatic carcinomas: intratumor heterogeneity and nonrandom pattern of chromosome aberrations. Genes Chromosomes. Cancer *23*, 81-99.

Gossen,M. and Bujard,H. (1992). Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc. Natl. Acad. Sci. U. S. A *89*, 5547-5551.

Gottlieb,T.M. and Oren,M. (1998). p53 and apoptosis. Semin. Cancer Biol. *8*, 359-368.

Hager,J.H. and Hanahan,D. (1999). Tumor cells utilize multiple pathways to down-modulate apoptosis. Lessons from a mouse model of islet cell carcinogenesis. Ann. N. Y. Acad. Sci. *887*, 150-163.

Hahn,S.A., Hoque,A.T., Moskaluk,C.A., da Costa,L.T., Schutte,M., Rozenblum,E., Seymour,A.B., Weinstein,C.L., Yeo,C.J., Hruban,R.H., and Kern,S.E. (1996). Homozygous deletion map at 18q21.1 in pancreatic cancer. Cancer Res. *56*, 490-494.

Hall,P.A., Meek,D., and Lane,D.P. (1996). p53--integrating the complexity. J. Pathol. *180*, 1-5.

Harper,J.W., Adami,G.R., Wei,N., Keyomarsi,K., and Elledge,S.J. (1993). The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell *75*, 805-816.

Harris,S.L. and Levine,A.J. (2005). The p53 pathway: positive and negative feedback loops. Oncogene *24*, 2899-2908.

Hermanek,P. (1998). Pathology and biology of pancreatic ductal adenocarcinoma. Langenbecks Arch. Surg. *383*, 116-120.

Herzenberg,L.A., Parks,D., Sahaf,B., Perez,O., Roederer,M., and Herzenberg,L.A. (2002). The history and future of the fluorescence activated cell sorter and flow cytometry: a view from Stanford. Clin. Chem. *48*, 1819-1827.

Hezel,A.F., Kimmelman,A.C., Stanger,B.Z., Bardeesy,N., and DePinho,R.A. (2006). Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev. *20*, 1218-1249.

Higuchi,Y., Asaumi,J., Murakami,J., Matsuzaki,H., Wakasa,T., Inoue,T., Shigehara,H., Konouchi,H., Hisatomi,M., Kawasaki,S., Hiraki,Y., and Kishi,K. (2003). Effects of p53 gene therapy in radiotherapy or thermotherapy of human head and neck squamous cell carcinoma cell lines. Oncol. Rep. *10*, 671-677.

Hillen,W. and Berens,C. (1994). Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu. Rev. Microbiol. *48*, 345-369.

Hollstein,M., Rice,K., Greenblatt,M.S., Soussi,T., Fuchs,R., Sorlie,T., Hovig,E., Smith-Sorensen,B., Montesano,R., and Harris,C.C. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. *22*, 3551-3555.

Hruban,R.H., Goggins,M., Parsons,J., and Kern,S.E. (2000). Progression model for pancreatic cancer. Clin. Cancer Res. *6*, 2969-2972.

Huh,J.J., Wolf,J.K., Fightmaster,D.L., Lotan,R., and Follen,M. (2003). Transduction of adenovirus-mediated wild-type p53 after radiotherapy in human cervical cancer cells. Gynecol. Oncol. *89*, 243-250.

Itoh,H., Komori,K., Okazaki,J., Mawatari,K., Kawasaki,K., Kuma,S., Eguchi,D., and Sugimachi,K. (1997). The effect of probucol on intimal thickening of autologous vein grafts in hyperlipidemic rabbit. Cardiovasc. Surg. *5*, 497-503.

Jacks,T. (1996). Lessons from the p53 mutant mouse. J. Cancer Res. Clin. Oncol. *122*, 319-327.

Jaenisch,R. (1988). Transgenic animals. Science *240*, 1468-1474.

Jemal,A., Murray,T., Ward,E., Samuels,A., Tiwari,R.C., Ghafoor,A., Feuer,E.J., and Thun,M.J. (2005). Cancer statistics, 2005. CA Cancer J. Clin. *55*, 10-30.

Jeong,J., Park,Y.N., Park,J.S., Yoon,D.S., Chi,H.S., and Kim,B.R. (2005). Clinical significance of p16 protein expression loss and aberrant p53 protein expression in pancreatic cancer. Yonsei Med. J. *46*, 519-525.

Joo,Y.E., Sohn,Y.H., Lee,W.S., Park,C.H., Choi,S.K., Rew,J.S., Park,C.S., and Kim,S.J. (2002). Expression of vascular endothelial growth factor and p53 in pancreatic carcinomas. Korean J. Intern. Med. *17*, 153-159.

Jura,N., Archer,H., and Bar-Sagi,D. (2005). Chronic pancreatitis, pancreatic adenocarcinoma and the black box in-between. Cell Res. *15*, 72-77.

Kameya,T., Shimosato,Y., Tumuraya,M., Ohsawa,N., and Nomura,T. (1976). Human gastric choriocarcinoma serially transplanted in nude mice. J. Natl. Cancer Inst. *56*, 325-332.

Karkkainen,M.J., Jussila,L., Ferrell,R.E., Finegold,D.N., and Alitalo,K. (2001). Molecular regulation of lymphangiogenesis and targets for tissue oedema. Trends Mol. Med. *7*, 18-22.

Keleg,S., Buchler,P., Ludwig,R., Buchler,M.W., and Friess,H. (2003). Invasion and metastasis in pancreatic cancer. Mol. Cancer *2*, 14.

Kim,A.L., Raffo,A.J., Brandt-Rauf,P.W., Pincus,M.R., Monaco,R., Abarzua,P., and Fine,R.L. (1999). Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J. Biol. Chem. *274*, 34924-34931.

Kirsten,W.H. and Mayer,L.A. (1969). Malignant lymphomas of extrathymic origin induced in rats by murine erythroblastosis virus. J. Natl. Cancer Inst. *43*, 735-746.

Korsmeyer,S.J. (1999). BCL-2 gene family and the regulation of programmed cell death. Cancer Res. *59*, 1693s-1700s.

Koshiba,T., Hosotani,R., Wada,M., Miyamoto,Y., Fujimoto,K., Lee,J.U., Doi,R., Arii,S., and Imamura,M. (1998). Involvement of matrix metalloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer *82*, 642-650.

Kranenburg,O., Gebbink,M.F., and Voest,E.E. (2004). Stimulation of angiogenesis by Ras proteins. Biochim. Biophys. Acta *1654*, 23-37.

Laemmli,U.K. (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature *227*, 680-685.

Laheru,D. and Jaffee,E.M. (2005). Immunotherapy for pancreatic cancer - science driving clinical progress. Nat. Rev. Cancer *5*, 459-467.

Lane,D.P. and Benchimol,S. (1990). p53: oncogene or anti-oncogene? Genes Dev. *4*, 1-8.

Lang,D., Miknyoczki,S.J., Huang,L., and Ruggeri,B.A. (1998). Stable reintroduction of wild-type P53 (MTmp53ts) causes the induction of apoptosis and neuroendocrine-like differentiation in human ductal pancreatic carcinoma cells. Oncogene *16*, 1593-1602.

Leber,T.M. and Balkwill,F.R. (1997). Zymography: a single-step staining method for quantitation of proteolytic activity on substrate gels. Anal. Biochem. *249*, 24-28.

Leist,M. and Nicotera,P. (1997). The shape of cell death. Biochem. Biophys. Res. Commun. *236*, 1-9.

Levrero,M., de,L., V, Costanzo,A., Gong,J., Wang,J.Y., and Melino,G. (2000). The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J. Cell Sci. *113 (Pt 10)*, 1661-1670.

Li,R., Sutphin,P.D., Schwartz,D., Matas,D., Almog,N., Wolkowicz,R., Goldfinger,N., Pei,H., Prokocimer,M., and Rotter,V. (1998). Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene *16*, 3269-3277.

Loukopoulos,P., Kanetaka,K., Takamura,M., Shibata,T., Sakamoto,M., and Hirohashi,S. (2004). Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas *29*, 193-203.

LOWRY,O.H., ROSEBROUGH,N.J., FARR,A.L., and RANDALL,R.J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. *193*, 265-275.

Mack,D.H., Vartikar,J., Pipas,J.M., and Laimins,L.A. (1993). Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature *363*, 281-283.

Malkin,D., Li,F.P., Strong,L.C., Fraumeni,J.F., Jr., Nelson,C.E., Kim,D.H., Kassel,J., Gryka,M.A., Bischoff,F.Z., Tainsky,M.A., and . (1990). Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science *250*, 1233-1238.

Malumbres,M. and Pellicer,A. (1998). RAS pathways to cell cycle control and cell transformation. Front Biosci. *3*, d887-d912.

Marin,M.C. and Kaelin,W.G., Jr. (2000). p63 and p73: old members of a new family. Biochim. Biophys. Acta *1470*, M93-M100.

Marme,D. (1999). [In Process Citation]. Chirurg *70*, 30-35.

Mathur,A., Hong,Y., Kemp,B.K., Barrientos,A.A., and Erusalimsky,J.D. (2000). Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. Cardiovasc. Res. *46*, 126-138.

Matsuda,T., Abe,T., Wu,J.L., Fujiki,M., and Kobayashi,H. (2005). Hypoxia-inducible factor-1alpha DNA induced angiogenesis in a rat cerebral ischemia model. Neurol. Res. *27*, 503-508.

McLure,K.G. and Lee,P.W. (1998). How p53 binds DNA as a tetramer. EMBO J. *17*, 3342-3350.

McLure,K.G. and Lee,P.W. (1999). p53 DNA binding can be modulated by factors that alter the conformational equilibrium. EMBO J. *18*, 763-770.

Mehlen,P. and Puisieux,A. (2006). Metastasis: a question of life or death. Nat. Rev. Cancer *6*, 449-458.

Michieli,P., Li,W., Lorenzi,M.V., Miki,T., Zakut,R., Givol,D., and Pierce,J.H. (1996). Inhibition of oncogene-mediated transformation by ectopic expression of p21Waf1 in NIH3T3 cells. Oncogene *12*, 775-784.

Mohammad,R.M., Al Katib,A., Pettit,G.R., Vaitkevicius,V.K., Joshi,U., Adsay,V., Majumdar,A.P., and Sarkar,F.H. (1998). An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. Clin. Cancer Res. *4*, 887-894.

Momand,J. and Zambetti,G.P. (1997). Mdm-2: "big brother" of p53. J. Cell Biochem. *64*, 343-352.

Moon,W.S., Rhyu,K.H., Kang,M.J., Lee,D.G., Yu,H.C., Yeum,J.H., Koh,G.Y., and Tarnawski,A.S. (2003). Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma? Mod. Pathol. *16*, 552-557.

Moore,P.S., Sipos,B., Orlandini,S., Sorio,C., Real,F.X., Lemoine,N.R., Gress,T., Bassi,C., Kloppel,G., Kalthoff,H., Ungefroren,H., Lohr,M., and Scarpa,A. (2001). Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch. *439*, 798-802.

Moretti,F., Farsetti,A., Soddu,S., Misiti,S., Crescenzi,M., Filetti,S., Andreoli,M., Sacchi,A., and Pontecorvi,A. (1997). p53 re-expression inhibits proliferation and restores differentiation of human thyroid anaplastic carcinoma cells. Oncogene *14*, 729-740.

Morgan,D.O. (1995). Principles of CDK regulation. Nature *374*, 131-134.

Mouta,C.C., Nasser,S.M., di Tomaso,E., Padera,T.P., Boucher,Y., Tomarev,S.I., and Jain,R.K. (2001). LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. *61*, 8079-8084.

Mukhopadhyay,D. and Datta,K. (2004). Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin. Cancer Biol. *14*, 123-130.

Mullis,K.B. and Faloona,F.A. (1987). Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction. Methods Enzymol. *155*, 335-350.

Munoz-Chapuli,R., Quesada,A.R., and Angel,M.M. (2004). Angiogenesis and signal transduction in endothelial cells. Cell Mol. Life Sci. *61*, 2224-2243.

Nakamori,S., Yashima,K., Murakami,Y., Ishikawa,O., Ohigashi,H., Imaoka,S., Yaegashi,S., Konishi,Y., and Sekiya,T. (1995). Association of p53 gene mutations with short survival in pancreatic adenocarcinoma. Jpn. J. Cancer Res. *86*, 174-181.

Nationales Krebsinstitut, Park City USA.
http://www.cancer.gov/cancertopics/factsheet/NCI/cancer-centers. 1999.
Ref Type: Conference Proceeding

Neid,M., Datta,K., Stephan,S., Khanna,I., Pal,S., Shaw,L., White,M., and Mukhopadhyay,D. (2004). Role of insulin receptor substrates and protein kinase C-zeta in vascular permeability factor/vascular endothelial growth factor expression in pancreatic cancer cells. J. Biol. Chem. *279*, 3941-3948.

Niedergethmann,M., Hildenbrand,R., Wostbrock,B., Hartel,M., Sturm,J.W., Richter,A., and Post,S. (2002). High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas *25*, 122-129.

Novina,C.D., Murray,M.F., Dykxhoorn,D.M., Beresford,P.J., Riess,J., Lee,S.K., Collman,R.G., Lieberman,J., Shankar,P., and Sharp,P.A. (2002). siRNA-directed inhibition of HIV-1 infection. Nat. Med. *8*, 681-686.

Ohki,R., Nemoto,J., Murasawa,H., Oda,E., Inazawa,J., Tanaka,N., and Taniguchi,T. (2000). Reprimo, a new candidate mediator of the p53-mediated cell cycle arrest at the G2 phase. J. Biol. Chem. *275*, 22627-22630.

Outzen,H.C. and Custer,R.P. (1975). Growth of human normal and neoplastic mammary tissues in the cleared mammary fat pad of the nude mouse. J. Natl. Cancer Inst. *55*, 1461-1466.

Overholt,S.M., Liu,T.J., Taylor,D.L., Wang,M., El Naggar,A.K., Shillitoe,E., Adler-Storthz,K., John,L.S., Zhang,W.W., Roth,J.A., and Clayman,G.L. (1997). Head and neck squamous cell growth suppression using adenovirus-p53-FLAG: a potential marker for gene therapy trials. Clin. Cancer Res. *3*, 185-191.

Owen-Schaub,L.B., Angelo,L.S., Radinsky,R., Ware,C.F., Gesner,T.G., and Bartos,D.P. (1995). Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. *94*, 1-8.

p53_database. http://p53.free.fr/Database/ p53_database.html. 2007.
Ref Type: Internet Communication

Papoutsi,M., Kurz,H., Schachtele,C., Marme,D., Christ,B., Prols,F., and Wilting,J. (2000). Induction of the blood-brain barrier marker neurothelin/HT7 in endothelial cells by a variety of tumors in chick embryos. Histochem. Cell Biol. *113*, 105-113.

Partanen,T.A. and Paavonen,K. (2001). Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc. Res. Tech. *55*, 108-121.

Pellegata,N.S., Sessa,F., Renault,B., Bonato,M., Leone,B.E., Solcia,E., and Ranzani,G.N. (1994). K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. *54*, 1556-1560.

Pennisi,E. (1999). Bracing p53 for the war on cancer. Science *286*, 2431.

Pepper,M.S. (2001). Lymphangiogenesis and tumor metastasis: myth or reality? Clin. Cancer Res. *7*, 462-468.

Pines,J. (1995). Cyclins and cyclin-dependent kinases: theme and variations. Adv. Cancer Res. *66*, 181-212.

Pluquet,O. and Hainaut,P. (2001). Genotoxic and non-genotoxic pathways of p53 induction. Cancer Lett. *174*, 1-15.

Prives,C. (1998). Signaling to p53: breaking the MDM2-p53 circuit. Cell *95*, 5-8.

Prives,C. and Hall,P.A. (1999). The p53 pathway. J. Pathol. *187*, 112-126.

Quaife,C.J., Pinkert,C.A., Ornitz,D.M., Palmiter,R.D., and Brinster,R.L. (1987). Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell *48*, 1023-1034.

Rak,J., Mitsuhashi,Y., Sheehan,C., Tamir,A., Viloria-Petit,A., Filmus,J., Mansour,S.J., Ahn,N.G., and Kerbel,R.S. (2000). Oncogenes and tumor angiogenesis: differential modes of

vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. *60*, 490-498.

Redston,M.S., Caldas,C., Seymour,A.B., Hruban,R.H., da Costa,L., Yeo,C.J., and Kern,S.E. (1994). p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res. *54*, 3025-3033.

Reuther,G.W. and Der,C.J. (2000). The Ras branch of small GTPases: Ras family members don't fall far from the tree. Curr. Opin. Cell Biol. *12*, 157-165.

Risau,W. and Flamme,I. (1995). Vasculogenesis. Annu. Rev. Cell Dev. Biol. *11*, 73-91.

Rosewicz,S. and Wiedenmann,B. (1997). Pancreatic carcinoma. Lancet *349*, 485-489.

Rozenblum,E., Schutte,M., Goggins,M., Hahn,S.A., Panzer,S., Zahurak,M., Goodman,S.N., Sohn,T.A., Hruban,R.H., Yeo,C.J., and Kern,S.E. (1997). Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. *57*, 1731-1734.

Ryding,A.D., Sharp,M.G., and Mullins,J.J. (2001). Conditional transgenic technologies. J. Endocrinol. *171*, 1-14.

Sambrook J and Russel D.M. (2001). Molecular Cloning - A Laboratory Manual. (Cold Spring Harbor, NY, USA: Cold Spring Harbor Laboratory Press).

Scheffzek,K., Ahmadian,M.R., and Wittinghofer,A. (1998). GTPase-activating proteins: helping hands to complement an active site. Trends Biochem. Sci. *23*, 257-262.

Schneider,G. and Schmid,R.M. (2003). Genetic alterations in pancreatic carcinoma. Mol. Cancer *2*, 15.

Schuler,M., Herrmann,R., De Greve,J.L., Stewart,A.K., Gatzemeier,U., Stewart,D.J., Laufman,L., Gralla,R., Kuball,J., Buhl,R., Heussel,C.P., Kommoss,F., Perruchoud,A.P., Shepherd,F.A., Fritz,M.A., Horowitz,J.A., Huber,C., and Rochlitz,C. (2001). Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study. J. Clin. Oncol. *19*, 1750-1758.

Schutte,M., Hruban,R.H., Geradts,J., Maynard,R., Hilgers,W., Rabindran,S.K., Moskaluk,C.A., Hahn,S.A., Schwarte-Waldhoff,I., Schmiegel,W., Baylin,S.B., Kern,S.E., and Herman,J.G. (1997). Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. *57*, 3126-3130.

Sedivy,R., Beck-Mannagetta,J., Haverkampf,C., Battistutti,W., and Honigschnabl,S. (2003). Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J. Oral Pathol. Med. *32*, 455-460.

Selivanova,G., Iotsova,V., Okan,I., Fritsche,M., Strom,M., Groner,B., Grafstrom,R.C., and Wiman,K.G. (1997). Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med. *3*, 632-638.

Selivanova,G., Ryabchenko,L., Jansson,E., Iotsova,V., and Wiman,K.G. (1999). Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell Biol. *19*, 3395-3402.

Semenza,G.L. (2001). HIF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. *13*, 167-171.

Serrano,M., Gomez-Lahoz,E., DePinho,R.A., Beach,D., and Bar-Sagi,D. (1995). Inhibition of ras-induced proliferation and cellular transformation by p16INK4. Science *267*, 249-252.

Sharkey,F.E. and Fogh,J. (1984). Considerations in the use of nude mice for cancer research. Cancer Metastasis Rev. *3*, 341-360.

Sherr,C.J. and Roberts,J.M. (1995). Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. *9*, 1149-1163.

Shi,Q. and Xie,K. (2000). Experimental animal models of pancreatic cancer (review). Int. J. Oncol. *17*, 217-225.

Shields,J.M., Pruitt,K., McFall,A., Shaub,A., and Der,C.J. (2000). Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. *10*, 147-154.

Shimosato,Y., Kameya,T., Nagai,K., Hirohashi,S., Koide,T., Hayashi,H., and Nomura,T. (1976). Transplantation of human tumors in nude mice. J. Natl. Cancer Inst. *56*, 1251-1260.

Sipos,B., Moser,S., Kalthoff,H., Torok,V., Lohr,M., and Kloppel,G. (2003). A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch. *442*, 444-452.

Sirivatanauksorn,V., Sirivatanauksorn,Y., and Lemoine,N.R. (1998). Molecular pattern of ductal pancreatic cancer. Langenbecks Arch. Surg. *383*, 105-115.

Smith,M.L. and Fornace,A.J., Jr. (2002). Chemotherapeutic targeting of p53. Cancer Biol. Ther. *1*, 56-57.

Soussi,T. and Beroud,C. (2001). Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer *1*, 233-240.

Soussi,T. and Beroud,C. (2003). Significance of TP53 mutations in human cancer: a critical analysis of mutations at CpG dinucleotides. Hum. Mutat. *21*, 192-200.

Soussi,T. and Lozano,G. (2005). p53 mutation heterogeneity in cancer. Biochem. Biophys. Res. Commun. *331*, 834-842.

Spandidos,D.A., Sourvinos,G., Tsatsanis,C., and Zafiropoulos,A. (2002). Normal ras genes: their onco-suppressor and pro-apoptotic functions (review). Int. J. Oncol. *21*, 237-241.

Stanbridge,E.J. and Perkins,F.T. (1976). Tumourigenicity testing in immunosuppressed mice: advantages and disadvantages. Dev. Biol. Stand. *37*, 211-217.

Standop,J., Schneider,M.B., Ulrich,A., and Pour,P.M. (2001). Experimental animal models in pancreatic carcinogenesis: lessons for human pancreatic cancer. Dig. Dis. *19*, 24-31.

Stetler-Stevenson,W.G. (1999). Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J. Clin. Invest *103*, 1237-1241.

Sullivan,A., Syed,N., Gasco,M., Bergamaschi,D., Trigiante,G., Attard,M., Hiller,L., Farrell,P.J., Smith,P., Lu,X., and Crook,T. (2004). Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo. Oncogene *23*, 3328-3337.

Takimoto,R., Wang,W., Dicker,D.T., Rastinejad,F., Lyssikatos,J., and el Deiry,W.S. (2002). The mutant p53-conformation modifying drug, CP-31398, can induce apoptosis of human cancer cells and can stabilize wild-type p53 protein. Cancer Biol. Ther. *1*, 47-55.

Tan,M.H. and Chu,T.M. (1985). Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour. Biol. *6*, 89-98.

Tang,R.F., Itakura,J., Aikawa,T., Matsuda,K., Fujii,H., Korc,M., and Matsumoto,Y. (2001). Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas *22*, 285-292.

Tao,W. and Levine,A.J. (1999). Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc. Natl. Acad. Sci. U. S. A *96*, 3077-3080.

Temin,H.M. and Mizutani,S. (1970). RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature *226*, 1211-1213.

Tilleray,V., Constantinou,C., and Clemens,M.J. (2006). Regulation of protein synthesis by inducible wild-type p53 in human lung carcinoma cells. FEBS Lett. *580*, 1766-1770.

Trahey,M. and McCormick,F. (1987). A cytoplasmic protein stimulates normal N-ras p21 GTPase, but does not affect oncogenic mutants. Science *238*, 542-545.

Uchima,Y., Sawada,T., Nishihara,T., Maeda,K., Ohira,M., and Hirakawa,K. (2004). Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas *29*, 123-131.

van de,W.M., Oving,I., Muncan,V., Pon Fong,M.T., Brantjes,H., van Leenen,D., Holstege,F.C., Brummelkamp,T.R., Agami,R., and Clevers,H. (2003). Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. EMBO Rep. *4*, 609-615.

van Oijen,M.G. and Slootweg,P.J. (2000). Gain-of-function mutations in the tumor suppressor gene p53. Clin. Cancer Res. *6*, 2138-2145.

Von Marschall,Z., Scholz,A., Stacker,S.A., Achen,M.G., Jackson,D.G., Alves,F., Schirner,M., Haberey,M., Thierauch,K.H., Wiedenmann,B., and Rosewicz,S. (2005). Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int. J. Oncol. *27*, 669-679.

Wadler,S., Makower,D., Yu,B., Tan,J.Y., Rozenblit,A., Kaufman,H., Edelman,M., Lane,M.E., and Zwiebel,J. (2002). Clinical applications of p53-directed gene therapy. Suppl Tumori *1*, S21.

Wagner,M., Greten,F.R., Weber,C.K., Koschnick,S., Mattfeldt,T., Deppert,W., Kern,H., Adler,G., and Schmid,R.M. (2001). A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. Genes Dev. *15*, 286-293.

Wang,W., Rastinejad,F., and el Deiry,W.S. (2003). Restoring p53-dependent tumor suppression. Cancer Biol. Ther. *2*, S55-S63.

Wang,W., Wang,C.Y., Dong,J.H., Chen,X., Zhang,M., and Zhao,G. (2005). Identification of effective siRNA against K-ras in human pancreatic cancer cell line MiaPaCa-2 by siRNA expression cassette. World J. Gastroenterol. *11*, 2026-2031.

Wang,Y., You,M., and Wang,Y. (2001). Alternative splicing of the K-ras gene in mouse tissues and cell lines. Exp. Lung Res. *27*, 255-267.

Watzinger,F., Mayr,B., Haring,E., and Lion,T. (1998). High sequence similarity within ras exons 1 and 2 in different mammalian species and phylogenetic divergence of the ras gene family. Mamm. Genome *9*, 214-219.

Weidner,N., Semple,J.P., Welch,W.R., and Folkman,J. (1991). Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N. Engl. J. Med. *324*, 1-8.

Weisz,B., Giehl,K., Gana-Weisz,M., Egozi,Y., Ben Baruch,G., Marciano,D., Gierschik,P., and Kloog,Y. (1999). A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice. Oncogene *18*, 2579-2588.

Wen,S.F., Mahavni,V., Quijano,E., Shinoda,J., Grace,M., Musco-Hobkinson,M.L., Yang,T.Y., Chen,Y., Runnenbaum,I., Horowitz,J., Maneval,D., Hutchins,B., and Buller,R. (2003). Assessment of p53 gene transfer and biological activities in a clinical study of adenovirus-p53 gene therapy for recurrent ovarian cancer. Cancer Gene Ther. *10*, 224-238.

Wu,G.S., Burns,T.F., McDonald,E.R., III, Jiang,W., Meng,R., Krantz,I.D., Kao,G., Gan,D.D., Zhou,J.Y., Muschel,R., Hamilton,S.R., Spinner,N.B., Markowitz,S., Wu,G., and el Deiry,W.S. (1997). KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. *17*, 141-143.

Xirodimas,D.P., Stephen,C.W., and Lane,D.P. (2001). Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53. Exp. Cell Res. *270*, 66-77.

Yokoyama,M., Yamanaka,Y., Friess,H., Buchler,M., and Korc,M. (1994). p53 expression in human pancreatic cancer correlates with enhanced biological aggressiveness. Anticancer Res. *14*, 2477-2483.

Yu,J. and Zhang,L. (2005). The transcriptional targets of p53 in apoptosis control. Biochem. Biophys. Res. Commun. *331*, 851-858.

Zhang,Y., Fujita,N., and Tsuruo,T. (1999). Caspase-mediated cleavage of p21Waf1/Cip1 converts cancer cells from growth arrest to undergoing apoptosis. Oncogene *18*, 1131-1138.